Clinical Trial Update: A Study of Tetrathiomolybdate (TM) Plus Capecitabine [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 study evaluating tetrathiomolybdate (TM) plus capecitabine for triple-negative breast cancer with residual disease; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Tetrathiomolybdate (tetrathiomolybdate)

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Triple Negative Breast Cancer, Residual Disease | Phase 1, Phase 2 | Status: RECRUITING